Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tilarginine + taxane
- Development stage
- Unknown
- Lead developer
- Galera Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tilarginine + taxane is an investigational combination therapy being developed by Galera Therapeutics for the treatment of metastatic and locally advanced triple-negative breast cancer (TNBC). The combination consists of tilarginine (L-NMMA), a small molecule pan-nitric oxide synthase (NOS) inhibitor, and a taxane-class chemotherapy agent such as docetaxel or paclitaxel. Tilarginine works by inhibiting NOS enzymes to reduce the production of nitric oxide, which is hypothesized to reverse chemotherapy resistance and modulate the tumor microenvironment in TNBC. Taxanes function by binding to and stabilizing microtubules, thereby inhibiting cell division and inducing apoptosis. This combination is administered intravenously and is currently in Phase 1/2 clinical development.
- Other names
- L-NMMA + taxanetilarginine + docetaxeltilarginine + paclitaxeltilarginine and taxane
02
Targets
NOS1 (nNOS)
Beyond the preview
Go deeper on tilarginine + taxane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tilarginine + taxane.